Century Therapeutics, INC. 8-K Filing

Ticker: IPSC · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1850119

Sentiment: neutral

Filing Stats: 1,248 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2025-12-09 08:05:35

Key Financial Figures

Filing Documents

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On December 9, 2025, the Board of Directors (the "Board") of Century Therapeutics, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, increased its size from six to eight directors and appointed Dr. Martin Murphy and Dr. Han Lee as directors of the Board, effective as of December 9, 2025 (the "Effective Date"). Dr. Murphy will serve as a Class III director with a term expiring at the 2027 Annual Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier resignation, death or removal, and Dr. Lee will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders, or until his successor is duly elected and qualified or until his earlier resignation, death or removal. Dr. Murphy will serve as a member of the Compensation and Nominating and Corporate Governance Committees of the Board and Dr. Lee will serve as member of the Compensation and Audit Committees of the Board. Dr. Murphy, 56, currently holds various board chair and director positions on several UK-based organizations including Synairgen plc, Cora Biosciences Limited and Legal & General UK Universities Ventures LP. Previously, Dr. Murphy served as co-founder of Syncona Limited and Chief Executive Officer and Investment Committee Chair of Syncona Investment Management Limited, or Syncona from October 2012 to November 2022. Prior to Syncona, Dr. Murphy served as a Managing Director of MVM Life Science Partners LLP from 2002 to 2012. Dr. Murphy also previously served on the board of Autolus Therapeutics plc from October 2013 to June 2024 and was a member of the Science Committee and Remuneration Committee during his tenure. Earlier in his career, Dr. Murphy was an Investment Manager at 3i Group plc from 2001 to 2002 and an Eng

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On December 9, 2025, the Company issued a press release announcing the appointments to the Board as discussed above. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference to such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Document 99.1 Press Release of Century Therapeutics, Inc., dated December 9, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENTURY THERAPEUTICS, INC. By: /s/ Brent Pfeiffenberger, PharmD, MBA Name: Brent Pfeiffenberger, PharmD, MBA Title: President and Chief Executive Officer Date: December 9, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing